Cue Biopharma, Inc.
CUE
$30.50
$0.501.67%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -2,856.10% | -426.69% | 121.28% | 12.19% | 30.80% |
| Total Depreciation and Amortization | -93.64% | -82.31% | 328.90% | -1,512.12% | -1.98% |
| Total Amortization of Deferred Charges | -- | -- | -10.00% | 11.11% | 0.00% |
| Total Other Non-Cash Items | 26,683.29% | 128.60% | -140.89% | 72.05% | -7.35% |
| Change in Net Operating Assets | 347.01% | -50.65% | -23.53% | -221.95% | 62.61% |
| Cash from Operations | -165.07% | -916.91% | 88.08% | -164.25% | 58.21% |
| Capital Expenditure | 100.00% | -- | -- | 100.00% | 82.00% |
| Sale of Property, Plant, and Equipment | -- | -- | 0.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 203.12% | -- | -- |
| Cash from Investing | 100.00% | -101.72% | 203.72% | -24,966.67% | 82.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -50.00% | 0.00% | 0.00% |
| Issuance of Common Stock | 706.86% | -97.22% | 998.10% | 33.11% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 9,709.48% | -96.78% | 949,100.00% | -99.99% | 1,879.80% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 109.42% | -169.69% | 197.75% | -210.00% | 254.00% |